TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18443815

Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) active recovery (60 W, approximately 35% VO(2max))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) active recovery (20 W, approximately 20% VO(2max))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 9
Study: 16571641

Group type: EXPERIMENTAL
Intervention: HP-HMG
Number of subjects: 184

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 184
Study: 12616007

Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 56
Study: 10719590

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (Zinnat, 2 x 250 mg/d)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 8958492

Group type: EXPERIMENTAL
Intervention: Gelatin 3%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6%
Number of subjects: 7
Study: 1313467

Group type: EXPERIMENTAL
Intervention: Oat bran diet (123 g oat bran for 4 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wheat bran diet (54 g wheat bran for 4 weeks)
Number of subjects: 23
Study: 3997300

Group type: EXPERIMENTAL
Intervention: Quinidine sulphate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Digoxin coadministration
Number of subjects: 6
Study: 31730042

Group type: EXPERIMENTAL
Intervention: mHealth intervention (Run4Love)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 300
Study: 28877566

Group type: EXPERIMENTAL
Intervention: Ginger capsules
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no ginger capsules)
Number of subjects: 49
Study: 25185858

Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) with Topical Negative Pressure (TNP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Topical Negative Pressure (TNP) alone
Number of subjects: 2
Study: 25336571

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study: 22209257

Group type: EXPERIMENTAL
Intervention: Rhinomanometry after nasal decongestant (ND) xylometazoline
Number of subjects: 71

Group type: COMPARATOR
Intervention: Rhinomanometry
Number of subjects: 71
Study: 20138368

Group type: EXPERIMENTAL
Intervention: Microplasmin 25 microg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Microplasmin 75 microg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Microplasmin 125 microg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 17951622

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 278
Study: 15338791

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg via Turbuhaler
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol 50 microg via Turbuhaler
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg via Diskhaler
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11249979

Group type: EXPERIMENTAL
Intervention: Azithromycin (31 patients) at a dose of 10 mg/kg once a week for 3 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Amoxicillin (40 patients) at a dose of 20 mg/kg per day for 3 months
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 9660523

Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Barnidipine + Atenolol
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Barnidipine + Enalapril
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Barnidipine (after enalapril failure)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 402

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 402
Study: 7851352

Group type: EXPERIMENTAL
Intervention: naproxen sodium 1100 mg 1 h prior to surgery
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: naproxen sodium 1100 mg immediately after surgery
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 2755866

Group type: EXPERIMENTAL
Intervention: Topical 70% dimethyl sulfoxide (DMSO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Topical 2% dimethyl sulfoxide (DMSO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.85% normal saline (Control)
Number of subjects: 84
Study: 341247

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (75 mg of living BCG on a scratched area once a week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 39
Study: 30665152

Group type: EXPERIMENTAL
Intervention: Relay model (Danish screening brief intervention and referral to treatment)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 561
Study: 28843768

Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone
Number of subjects: 929

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 929
Study: 26524801

Group type: EXPERIMENTAL
Intervention: r‐FSH
Number of subjects: 45

Group type: COMPARATOR
Intervention: hMG
Number of subjects: 45
Study: 23607997

Group type: EXPERIMENTAL
Intervention: Fearless Dominance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-Centered Impulsivity
Number of subjects: 0
Study: 21332248

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 12262

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12262
Study: 19836621

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 60
Study: 17602060

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®) plus carboplatin and paclitaxel (BV/CP)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel alone (CP)
Number of subjects: 878
Study: 16176400

Group type: EXPERIMENTAL
Intervention: Active SLIT for 1 year, followed by 2 years of active treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active SLIT for 2 years
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active SLIT for 3 years
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo SLIT for 1 year
Number of subjects: 24
Study: 11961328

Group type: EXPERIMENTAL
Intervention: Colgate Total with the addition of 10% xylitol (Total‐Xylitol)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Colgate Total
Number of subjects: 155

Group type: COMPARATOR
Intervention: Colgate Total without triclosan and without xylitol
Number of subjects: 155
Study: 10412270

Group type: EXPERIMENTAL
Intervention: Bcl2 expression in euploid cases
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bax expression in euploid cases
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bcl2 expression in aneuploid cases
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bax expression in aneuploid cases
Number of subjects: 114
Study: 7587851

Group type: EXPERIMENTAL
Intervention: Multiple insulin injection therapy (MIT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 76
Study: 2262314

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62
Study: 424591

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg)
Number of subjects: 81
Study: 31887277

Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR)
Number of subjects: 100
Study: 30720541

Group type: EXPERIMENTAL
Intervention: Topical ripasudil 0.4% (Glanatec) 4 times a day for 2 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: No ripasudil (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical ripasudil 0.4% (Glanatec)
Number of subjects: 18
Study: 27528215

Group type: EXPERIMENTAL
Intervention: Education based on phosphorus‐reducing techniques in food preparation and two hospital meals prepared using suggested cooking methods
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard education program
Number of subjects: 47
Study: 26442397

Group type: EXPERIMENTAL
Intervention: Neostigmine group (group N) received bupivacaine 20 mg combined with 25 µg neostigmine.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C) received bupivacaine 20 mg combined with 0.5ml distilled water.
Number of subjects: 60
Study: 23833985

Group type: EXPERIMENTAL
Intervention: Surgery with skin grafting (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery without skin grafting (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgery with skin grafting (Group A)
Number of subjects: 120
Study: 21829046

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 28
Study: 19268411

Group type: EXPERIMENTAL
Intervention: Conversion from catheter to permanent vascular access (AVF/AVG)
Number of subjects: 4532

Group type: COMPARATOR
Intervention: Conversion from permanent vascular access (AVF/AVG) to catheter
Number of subjects: 4532
Study: 16876171

Group type: EXPERIMENTAL
Intervention: B vitamins and antioxidants (verum)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 123
Study: 14681344

Group type: EXPERIMENTAL
Intervention: YH1885 60 mg single dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 100 mg single dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 150 mg single dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 200 mg single dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 300 mg single dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 150 mg multiple doses (once-daily for 7 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: YH1885 300 mg multiple doses (once-daily for 7 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11792041

Group type: EXPERIMENTAL
Intervention: Ultra-fast low-angle rapid acquisition and relaxation enhancement (UFLARE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine T2-weighted spin echo images
Number of subjects: 100
Study: 9488264

Group type: EXPERIMENTAL
Intervention: Cataract surgery in patients with PSX
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cataract surgery in control patients
Number of subjects: 50
Study: 7988781

Group type: COMPARATOR
Intervention: Microalbuminuria group (n = 14)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Macroalbuminuria group (n = 11)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Microalbuminuria and Macroalbuminuria groups
Number of subjects: 37
Study: 2471438

Group type: EXPERIMENTAL
Intervention: Oral iron
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 47702

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparinoid Ro 1-8307
Number of subjects: 0
Study: 30480487

Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch Injection (ABPI)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Hydrogel Plug
Number of subjects: 453
Study: 28500875

Group type: EXPERIMENTAL
Intervention: Mandibular setback (group A; n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Advancement genioplasty (group B; n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mandibular setback plus advancement genioplasty (group C; n = 12)
Number of subjects: 35
Study: 25864150

Group type: EXPERIMENTAL
Intervention: Peer group intervention (six sessions offered to same-gender groups by trained volunteers)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Peer group intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: Non-participants in the intervention district
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Community HIV prevention
Number of subjects: 415
Study: 23721033

Group type: EXPERIMENTAL
Intervention: Occlusal appliance therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (palatal appliance)
Number of subjects: 120
Study: 21590762

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 99

Group type: COMPARATOR
Intervention: Spinal analgesia
Number of subjects: 99

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 99
Study: 19040623

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 80 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 40 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16546471

Group type: EXPERIMENTAL
Intervention: Isoflavone intake (75 mg of isoflavones conjugates per day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Isoflavone combined with walking
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo combined with walking (3 times per week)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 15618834

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 10
Study: 11418493

Group type: EXPERIMENTAL
Intervention: PROP filter papers
Number of subjects: 742
Study: 9302754

Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine
Number of subjects: 106
Study: 8437326

Group type: EXPERIMENTAL
Intervention: Triple-lumen catheters with Vitacuff application and a semiocclusive dressing material
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple-lumen tunneled catheters with collodion as a dressing material
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple-lumen tunneled catheters with a semiocclusive dressing
Number of subjects: 50
Study: 2876575

Group type: COMPARATOR
Intervention: Pancuronium (P)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atracurium (A)
Number of subjects: 30
Study: 29630706

Group type: EXPERIMENTAL
Intervention: Narrative emphasizing violence
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Narrative emphasizing systemic barriers to treatment
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Narrative emphasizing successful treatment and recovery
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1326
Study: 26823137

Group type: EXPERIMENTAL
Intervention: High volume IV fluid (20 mL/kg bolus + 1.5 × maintenance rate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low volume IV fluid (10 mL/kg bolus + 1.25 × maintenance rate)
Number of subjects: 50
Study: 24766353

Group type: EXPERIMENTAL
Intervention: Hammock sleep (n = 14)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bassinet sleep (n = 9)
Number of subjects: 23
Study: 22920928

Group type: EXPERIMENTAL
Intervention: Presence of Q waves on baseline electrocardiogram
Number of subjects: 4530

Group type: COMPARATOR
Intervention: Time from symptom onset to PCI >3 hours
Number of subjects: 4530
Study: 20106580

Group type: EXPERIMENTAL
Intervention: 35 mg of tartrazine dye
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18179315

Group type: EXPERIMENTAL
Intervention: Implicit tests with high structural fit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit tests with high structural fit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit tests with low structural fit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit tests with low structural fit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect misattribution procedure
Number of subjects: 0
Study: 15938775

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided immature follicle aspiration (IMFA) with slight amount of human menopausal gonadotropin (hMG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no hMG)
Number of subjects: 71
Study: 12600913

Group type: EXPERIMENTAL
Intervention: High-dose milrinone (75-microg/kg bolus followed by a 0.75-microg/kg per min infusion for 35 hours)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Low-dose milrinone (25-microg/kg bolus followed by a 0.25-microg/kg per min infusion for 35 hours)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: High-dose milrinone
Number of subjects: 238
Study: 11124928

Group type: EXPERIMENTAL
Intervention: 4% w/w amethocaine gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9513912

Group type: EXPERIMENTAL
Intervention: Chronic biopsy scores at months 3 and 6
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Late rejections (months 4 to 6)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) levels (months 1 to 2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Donor age and chronic biopsy score > or = 2 at 6 months
Number of subjects: 71
Study: 7892022

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg (slow-release formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3150950

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg per day for 5 days (CC-5)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg per day for 15 days (CC-15)
Number of subjects: 5
Study: 31736279

Group type: EXPERIMENTAL
Intervention: Macular buckling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 80
Study: 29912467

Group type: EXPERIMENTAL
Intervention: Trans-disciplinary advanced allied health practitioners (AHPs), n = 172
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard allied health (AH), n = 84
Number of subjects: 256
Study: 28577395

Group type: EXPERIMENTAL
Intervention: More-skilled participants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Less-skilled participants
Number of subjects: 34
Study: 25993904

Group type: COMPARATOR
Intervention: Conventional pressure dressing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: New compression tool
Number of subjects: 46
Study: 23888935

Group type: EXPERIMENTAL
Intervention: Fasted conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0
Study: 21740390

Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TBNA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA in subcarinal lymph nodes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TBNA in subcarinal lymph nodes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA in other mediastinal lymph nodes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TBNA in other mediastinal lymph nodes
Number of subjects: 60
Study: 19225700

Group type: EXPERIMENTAL
Intervention: Group education (54 subjects)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Individual education (50 subjects)
Number of subjects: 104
Study: 16352692

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Alendronate (continuation)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: COMPARATOR
Intervention: Discontinuation of alendronate
Number of subjects: 99
Study: 15094260

Group type: EXPERIMENTAL
Intervention: Paroxetine only
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Paroxetine combined with cognitive group-therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (patients with personality disorder or social phobia)
Number of subjects: 73
Study: 10757131

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: nalmefene
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 9547164

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of IL-6 in AD patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of soluble IL-6 receptor (sIL-6R) in AD patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of soluble gp130 (sgp130) in AD patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of sgp130 in all individuals
Number of subjects: 35
Study: 8341439

Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream 0.1% applied daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Betamethasone valerate cream 0.1% applied twice daily
Number of subjects: 58
Study: 31009427

Group type: EXPERIMENTAL
Intervention: High-Frequency Resistance Training (HFRT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-Frequency Resistance Training (LFRT)
Number of subjects: 18
Study: 31633603

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Usual patient care
Number of subjects: 287
Study: 29141040

Group type: COMPARATOR
Intervention: Medical therapy (oral contraceptive pills Nordette® or Naproxen Naprosyn®)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Radiofrequency endometrial ablation (REA)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Direct medical costs for REA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Total costs including indirect costs for REA
Number of subjects: 67
Study: 25377934

Group type: EXPERIMENTAL
Intervention: Video modelling intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control video (oral hygiene instruction)
Number of subjects: 80
Study: 23937387

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (25-200 mg bid)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Oxycodone CR (5-40 mg bid)
Number of subjects: 343
Study: 20952051

Group type: EXPERIMENTAL
Intervention: Hybrid resin composite with an intermediate layer of flowable resin composite
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hybrid resin composite without an intermediate layer of flowable resin composite
Number of subjects: 46